SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 1536.
  • 2
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 3
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796802.
  • 4
    zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 6908.
  • 5
    van Muyden RC, ter Harmsel BW, Smedts FM, Hermans J, Kuijpers JC, Raikhlin NT, Petrov S, Lebedev A, Ramaekers FC, Trimbos JB, Kleter B, Quint WG. Detection and typing of human papillomavirus in cervical carcinomas in Russian women: a prognostic study. Cancer 1999; 85: 20116.
  • 6
    Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infection. J Clin Virol 2005; 32: S43S51.
  • 7
    Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, Stolz E, Herbrink P. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996; 34: 7457.
  • 8
    Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 2006; 118: 2435.
  • 9
    Quint WG, Pagliusi SR, Lelie N, de Villiers EM, Wheeler CM. Results of the first world health organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol 2006; 44: 5719.
  • 10
    Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 27885.
  • 11
    Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 1015.
  • 12
    Burger RA, Monk BJ, Kurosaki T, Anton-Culver H, Vasilev SA, Berman ML, Wilczynski SP. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996; 88: 13618.
  • 13
    Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiere A, Clough K, Favre M, Pouillart P, Sastre-Garau X. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol 1998; 16: 26139.
  • 14
    Schwartz SM, Daling JR, Shera KA, Madeleine MM, McKnight B, Galloway DA, Porter PL, McDougall JK. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 2001; 19: 190615.
  • 15
    Huang LW, Chao SL, Hwang JL. Human papillomavirus-31-related types predict better survival in cervical carcinoma. Cancer 2004; 100: 32734.
  • 16
    Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, Lin CY, Yan CC, Chou HH, Huang KG, Huang HJ, Wu TI et al. Comparison between the hybrid capture II test and a SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol 2006; 44: 17339.
  • 17
    Huang HJ, Huang SL, Lin CY, Lin RW, Chao FY, Chen MY, Chang TC, Hsueh S, Hsu KH, Lai CH. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer 2004; 14: 63949.
  • 18
    Matsukura T, Sugase M. Relationships between 80 human papillomavirus genotypes and different grades of cervical intraepithelial neoplasia: association and causality. Virology 2001; 283: 13947.
  • 19
    Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 2001; 10: 4552.
  • 20
    Chen TM, Chen CA, Wu CC, Huang SC, Chang CF, Hsieh CY. The genotypes and prognostic significance of human papillomaviruses in cervical cancer. Int J Cancer 1994; 57: 1814.
  • 21
    Bachtiary B, Obermair A, Dreier B, Birner P, Breitenecker G, Knocke TH, Selzer E, Potter R. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int J Cancer 2002; 102: 23743.
  • 22
    Sebbelov AM, Davidson M, Kruger Kjaer S, Jensen H, Gregoire L, Hawkins I, Parkinson AJ, Norrild B. Comparison of human papillomavirus genotypes in archival cervical cancer specimens from Alaska natives, Greenland natives and Danish Caucasians. Microbes Infect 2000; 2: 1216.
  • 23
    Stanczuk GA, Kay P, Sibanda E, Allan B, Chirara M, Tswana SA, Bergstrom S, Williamson AL. Typing of human papillomavirus in Zimbabwean patients with invasive cancer of the uterine cervix. Acta Obstet Gynecol Scand 2003; 82: 7626.
  • 24
    Huang S, Afonina I, Miller BA, Beckmann AM. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 1997; 70: 40811.
  • 25
    Li J, Gerhard DS, Zhang Z, Huettner PC, Wright J, Nguyen L, Lu D, Rader JS. Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. J Clin Microbiol 2003; 41: 556371.
  • 26
    Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36: 30207.
  • 27
    van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 77987.
  • 28
    van Doorn LJ, Quint W, Kleter B, Molijn A, Colau B, Martin MT, Kravang I, Torrez-Martinez N, Peyton CL, Wheeler CM. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 2002; 40: 97983.
  • 29
    Chen SL, Han CP, Tsao YP, Lee JW, Yin CS. Identification and typing of human papillomavirus in cervical cancers in Taiwan. Cancer 1993; 72: 193945.
  • 30
    Liaw KL, Hsing AW, Schiffman MH, You SL, Zhang T, Burk R, Chen CJ. Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women. Int J Cancer 1997; 73: 7756.
  • 31
    Lai HC, Sun CA, Yu MH, Chen HJ, Liu HS, Chu TY. Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. Int J Cancer 1999; 84: 5537.
  • 32
    Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, Li GD, Tam JS, et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 2002; 100: 32731.
  • 33
    Wu Y, Chen Y, Li L, Yu G, Zhang Y, He Y. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol 2006; 35: 2649.
  • 34
    Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Sideri M, Pecorelli S. Carcinoma of the cervix uteri. J Epidemiol Biostat 2001; 6: 743.
  • 35
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Manhart LE, Koutsky LA, Baer A, Saroiu S, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 164551.
  • 36
    Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 2718.
  • 37
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 175765.
  • 38
    Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 124755.
  • 39
    Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker-van Marle E. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer 2000; 83: 5615.
  • 40
    Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94101.